◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CBIO

Crescent Biopharma, Inc. (CBIO) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Crescent Biopharma, Inc. (CBIO) operates in the BIOTECHNOLOGY industry and is headquartered in Waltham, United States with about 69 employees. Its market capitalization is roughly $776 million. In the fiscal year ended 2025-12-31, CBIO reported $11M in revenue and ($154M) in net income.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Interactive charts & full statements → Open the CBIO valuation workbench →

CBIO Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$42M	$11M	—	$0M	$0M	$1M	$10M	—	—	—	$0M	$20M	$15M	$4M	$15M	$4M
Gross Profit	—	$11M	$0M	$0M	$0M	$1M	$10M	($1M)	$0M	$0M	$0M	$20M	$15M	$4M	$15M	$4M
Gross Margin %	—	100.0%	—	100.0%	100.0%	100.0%	100.0%	—	—	—	100.0%	100.0%	100.0%	100.0%	100.0%	97.8%
Operating Income (EBIT)	($168M)	($153M)	($50M)	($39M)	($47M)	($63M)	($52M)	($61M)	($52M)	($34M)	($32M)	($13M)	($11M)	($11M)	$4M	($6M)
Operating Margin %	-396.9%	-1407.5%	—	-392752.9%	-63204.4%	-5470.7%	-506.8%	—	—	—	-172505.3%	-63.7%	-74.1%	-265.6%	23.8%	-159.5%
Net Income	($163M)	($154M)	($49M)	($37M)	($47M)	($63M)	($51M)	($54M)	($48M)	($33M)	($32M)	($13M)	($11M)	($11M)	$4M	($6M)
Net Margin %	-383.9%	-1419.6%	—	-368994.2%	-62251.7%	-5469.0%	-502.1%	—	—	—	-171945.1%	-63.6%	-74.0%	-265.6%	24.0%	-160.3%
EBITDA	($163M)	($150M)	($44M)	($39M)	($47M)	($63M)	($51M)	($57M)	($51M)	($34M)	($32M)	($13M)	($11M)	($10M)	$4M	($6M)
Earnings Per Share (EPS)	$-7.58	$-14.78	$-63.22	$-37.00	$-47.00	$-63.00	$-111.60	$-125.11	$-117.61	$-113.22	$-149.65	$-67.17	$-60.27	$-199.32	$305.64	$-32.55
Shares Outstanding (M)	31M	—	1M	1M	1M	1M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CBIO Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$1M	$11M	$31M	$0M	$0M	$0M	—
Gross Profit	—	$1M	$11M	$29M	$0M	—	$0M	$0M
Gross Margin %	—	100.0%	100.0%	94.7%	—	—	—	—
Operating Income (EBIT)	($26M)	($25M)	($91M)	($26M)	($21M)	($14M)	($17M)	($11M)
Operating Margin %	—	-2380.1%	-843.7%	-84.7%	—	—	—	—
Net Income	($23M)	($23M)	($92M)	($25M)	($22M)	($15M)	($18M)	($10M)
Net Margin %	—	-2240.9%	-852.1%	-80.5%	—	—	—	—
EBITDA	($25M)	($23M)	($90M)	($25M)	($21M)	($14M)	$18M	($6M)
Earnings Per Share (EPS)	$-0.74	$-0.77	$-4.58	$-1.49	$-5.65	$-19.63	$-18.00	$-10.00
Shares Outstanding (M)	31M	30M	20M	17M	4M	1M	1M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CBIO Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($73M)	($72M)	($31M)	($35M)	($46M)	($57M)	($39M)	($52M)	($43M)	($30M)	($30M)	($8M)	($4M)	($16M)	($10M)	$14M
Capital Expenditures (CapEx)	$81M	$73M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($154M)	($144M)	($31M)	($35M)	($47M)	($58M)	($39M)	($52M)	($43M)	($30M)	($30M)	($9M)	($4M)	($16M)	($11M)	$14M
FCF Margin %	-361.9%	-1332.1%	—	-349013.0%	-62055.6%	-4958.3%	-386.8%	—	—	—	-164516.0%	-42.4%	-29.9%	-391.2%	-70.7%	358.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CBIO Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($19M)	($9M)	($27M)	($18M)	($16M)	($11M)	($4M)	($8M)
Capital Expenditures (CapEx)	$0M	$8M	$72M	$1M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($19M)	($17M)	($99M)	($18M)	($17M)	($11M)	($4M)	($8M)
FCF Margin %	—	-1644.3%	-912.3%	-59.3%	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CBIO Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$183M	$240M	$36M	$45M	$52M	$94M	$143M	$168M	$215M	$129M	$42M	$48M	$57M	$5M	$18M	$29M
Cash & Cash Equivalents	$172M	$213M	$35M	$42M	$48M	$90M	$137M	$158M	$210M	$124M	$40M	$47M	$55M	$2M	$17M	$28M
Total Liabilities	$20M	$37M	$51M	$7M	$9M	$13M	$15M	$14M	$9M	$9M	$7M	$8M	$6M	$2M	$6M	$20M
Total Debt (Short + Long-Term)	$0M	$0M	$38M	$1M	$1M	$1M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$163M	$203M	($15M)	$38M	$43M	$82M	$128M	$154M	$205M	$120M	$35M	$40M	$51M	$3M	$13M	$8M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CBIO viewer.

Other Companies in BIOTECHNOLOGY

CLYM · Climb Bio Inc — $807 million
FDMT · 4D Molecular Therapeutics Inc — $779 million
DBVT · DBV Technologies — $776 million
ACHV · Achieve Life Sciences Inc — $776 million
DSGN · Design Therapeutics Inc — $766 million
NGNE · Neurogene Inc — $758 million
MNPR · Monopar Therapeutics Inc — $754 million
ARGX · argenx NV ADR — $62 billion

← CBIL All “C” companies CBK →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.